This Week
  • Pharos Systems International has grown to become a multinational enterprise.

  • The Market at I-Square is a milestone for the $18 million project in Irondequoit.

  • Leonard Brock grew up very poor and tries to help others in need.

  • For employees today, paid leave is one of the most important benefits.

  • New Simon School dean Andrew Ainslie has a plan to raise its national stature.

  • The RBJ 75 supplement presents a list of the 75 largest private-sector employers.

What now for B&L?

Rochester Business Journal
June 7, 2013

Last week's announcement that private-equity owners had agreed to sell Bausch & Lomb Holdings Inc. to Valeant Pharmaceuticals International Inc. brought no expressions of shock or even great surprise.
 
Instead, the local reaction was disappointment-in part because Bausch & Lomb had been on the path to becoming a public company again-and pessimism about what this will mean for B&L employees and the community.
 
This is understandable. No one here will welcome the day when, after 160 years, Bausch & Lomb is no longer an independent, Rochester-based company.
 
But let's not assume we know what lies ahead. Many people thought Warburg Pincus ownership would be devastating for Bausch & Lomb and the community. Yet has that really been the case?
 
Since 2007, Bausch & Lomb-unlike Eastman Kodak Co. and Xerox Corp.-has increased its local workforce. And as its recent S-1 filing shows, the company has increased revenues and improved its bottom line over the past three years.
 
The registration statement also underscores what B&L CEO Brent Saunders told the RBJ last summer: Bausch & Lomb six years ago was a company in need of a transformation. His focus, Mr. Saunders said, was to make up "for at least two and maybe three decades of lost innovation and opportunity" and "(build) the strongest company possible."
 
That Valeant is willing to pay $8.7 billion for Bausch & Lomb suggests this focus has been the correct.
 
Will Bausch & Lomb's new owner stay on this course? So far, the signals have been mixed. Valeant CEO Michael Pearson told analysts he wants Bausch & Lomb's vision care, surgical and pharmaceutical divisions to rise to No. 1 in their markets.
 
Yet he also said research and development would not be a big driver of B&L growth-and he thinks $800 million in cost savings can be achieved with the merged companies.
 
In the best-case scenario, Valeant with Bausch & Lomb will grow on a scale that neither firm could have achieved separately. Let's hope that happens.

Meanwhile, our community must maintain its focus: developing a broad-based, innovative economy not dependent on the success of any single company.

6/7/13 (c) 2013 Rochester Business Journal. To obtain permission to reprint this article, call 585-546-8303 or email service@rbj.net.


What You're Saying 

There are no comments yet. Be the first to add yours!

Post Your Own Comment

 
Username:
Password:

Not registered? Sign up now!
 

To Do   Text Size
Post CommentPost A Comment eMail Size1
View CommentsView All Comments PrintPrint Size2
ReprintsReprints Size3
  • E-mailed
  • Commented
  • Viewed
RBJ   Google